8-K: Agenus Regains Rights to AGEN1777 as Bristol Myers Squibb Terminates License Agreement

Bristol Myers Squibb has terminated its license agreement for Agenus's AGEN1777, returning full rights to Agenus effective January 26, 2025.

Summary

• Agenus has received notice from Bristol Myers Squibb (BMS) that they are terminating the license agreement for AGEN1777, a TIGIT bispecific antibody program.
• The termination is part of a broader strategic realignment of BMS's development pipeline and will be effective January 26, 2025.
• Agenus originally granted BMS an exclusive license in May 2021, receiving a $200 million upfront payment, plus $20 million in December 2021 and $25 million in January 2024 for milestone payments.
• BMS is returning all rights to AGEN1777 to Agenus, including an exclusive, royalty-free, worldwide, and sublicensable license to BMS know-how and patent rights.
• BMS will also assign all regulatory registrations, applications, authorizations, and approvals related to AGEN1777 to Agenus.
• Agenus will not incur any early termination penalties and intends to explore further development or relicensing of AGEN1777, potentially in combination with its other immuno-oncology agents.
• The initial licensing of AGEN1777 to BMS occurred before any clinical data was available, but significant safety data and indications of clinical activity have since been generated.

Sentiment

Score: 5

Explanation: While regaining full rights to AGEN1777 is a positive, the termination of the BMS agreement introduces uncertainty and the need for further investment. The loss of potential future revenue from BMS is a negative.

Positives

• Agenus regains full control of AGEN1777, a promising TIGIT bispecific antibody program.
• Agenus will receive an exclusive, royalty-free, worldwide, and sublicensable license to BMS know-how and patent rights related to AGEN1777.
• Agenus will receive all regulatory registrations, applications, authorizations, and approvals for AGEN1777 from BMS.
• Agenus will not incur any early termination penalties.
• The company has the opportunity to further develop or relicense AGEN1777, potentially increasing its value.
• Significant safety data and indications of clinical activity have been generated since the initial licensing of AGEN1777.

Negatives

• The termination of the BMS license agreement means Agenus will no longer receive potential future milestone payments or royalties from BMS for AGEN1777.
• Agenus will need to invest further resources to develop or relicense AGEN1777.

Risks

• Agenus may face challenges in securing a new partner or funding for the further development of AGEN1777.
• There is no guarantee that Agenus will be able to successfully develop or relicense AGEN1777.
• The termination of the agreement could negatively impact investor sentiment.

Future Outlook

Agenus intends to explore further development and/or relicensing of AGEN1777, including potential combinations with its portfolio of synergistic immuno-oncology agents.

Management Comments

• Agenus intends to explore further development and/or relicensing of this molecule, including potential combinations with our portfolio of synergistic immuno-oncology agents.

Industry Context

The termination of the agreement reflects a broader trend of pharmaceutical companies re-evaluating their pipelines and focusing on core assets. This can create opportunities for smaller biotech companies like Agenus to regain control of promising assets and pursue alternative development strategies.

Comparison to Industry Standards

• The return of licensed assets is not uncommon in the pharmaceutical industry, as companies adjust their strategic priorities.
• Other companies such as Xencor have also seen similar returns of licensed assets, highlighting the dynamic nature of drug development partnerships.
• The $245 million in upfront and milestone payments received by Agenus is within the typical range for early-stage licensing agreements in the biotech sector.
• The decision by BMS to terminate the agreement despite positive clinical data suggests a shift in their strategic focus, rather than a reflection of the potential of AGEN1777.

Stakeholder Impact

• Shareholders may react negatively to the loss of the BMS partnership, but positively to the potential for Agenus to develop or relicense the asset.
• Employees may be impacted by the change in development strategy for AGEN1777.
• Potential partners may be interested in licensing AGEN1777 from Agenus.

Next Steps

• Agenus will explore further development and/or relicensing of AGEN1777.
• Agenus will evaluate potential combinations of AGEN1777 with its other immuno-oncology agents.

Key Dates

Keywords

AGEN1777, TIGIT, bispecific antibody, license agreement, Bristol Myers Squibb, immuno-oncology, drug development, clinical trials, relicensing